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previously found in patients with inflammatory liver dis-
eases or liver cancer. All significantly impair the transporter 
with a range of phenotypes exhibited, including low abun-
dance, intracellular retention, and reduced floppase activity, 
suggesting that ABCB4 deficiency is the root cause of the 
pathology in these cases.
Keywords MDR3 · Inflammatory liver disease · 
Sclerosing cholangitis · Biliary cirrhosis · Bile flow · Liver 
cancer · Cholestasis
Introduction
Cholesterol is a planar amphiphile comprising three 
cyclohexane rings (rings A to C) and one cyclopentane 
ring (ring D), with a hydroxyl group on the A ring and a 
hydrocarbon carbon tail on the D ring. It readily interca-
lates into the plasma membrane where the hydrophobic 
steroid rings and hydrocarbon tail intercalate between the 
acyl chains of the membrane lipids, and the hydroxyl inter-
acts with their polar head groups. In the liver, cholesterol is 
catabolised primarily into bile acids. The simplest primary 
bile acid (chenodeoxycholic acid) has a second hydroxyl on 
the B ring and a carboxyl end to the hydrocarbon tail [1]. It 
is no longer planar and the axis of amphiphilicity extends 
the length of the molecule giving it a hydrophobic and a 
hydrophilic face. These features make bile acids extremely 
effective at solubilising dietary fat. The same features also 
cause bile acids to solubilise lipids from cell membranes 
and they are, therefore, inherently cytotoxic. On secretion 
from the hepatocyte across the canalicular membrane by 
the bile salt export pump (BSEP, ABCB11), monomeric 
bile acids pose a cytotoxic threat to the hepatocytes and 
cholangiocytes that line the biliary tree. Higher eukaryotes 
Abstract Bile salts are natural detergents required to sol-
ubilise dietary fat and lipid soluble vitamins. They are syn-
thesised in hepatocytes and secreted into the luminal space 
of the biliary tree by the bile salt export pump (BSEP), an 
ATP-binding cassette (ABC) transporter in the canalicular 
membrane. BSEP deficiency causes cytotoxic accumula-
tion of bile salts in the hepatocyte that results in mild-to-
severe forms of cholestasis. The resulting inflammation can 
also progress to hepatocellular cancer via a novel mecha-
nism involving upregulation of proliferative signalling 
pathways. A second ABC transporter of the canalicular 
membrane is also critical for bile formation. ABCB4 flops 
phosphatidylcholine into the outer leaflet of the membrane 
to be extracted by bile salts in the canalicular space. These 
mixed micelles reduce the detergent action of the bile salts 
and protect the biliary tree from their cytotoxic activity. 
ABCB4 deficiency also causes cholestasis, and might be 
expected to cause cholangitis and predispose to liver can-
cer. Non-synonymous SNPs in ABCB4 have now been 
described in patients with liver cancer or with inflamma-
tory liver diseases that are known to predispose to cancer, 
but data showing that the SNPs are sufficiently deleterious 
to be an etiological factor are lacking. Here, we report the 
first characterisation at the protein level of six ABCB4 vari-
ants (D243A, K435T, G535D, I490T, R545C, and S978P) 
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have therefore evolved mechanisms to protect the biliary 
tree from these hepatic metabolites. Excess phosphatidyl-
choline (PC) is flopped into the outer leaflet of the cana-
licular membrane of hepatocytes by a second ABC trans-
porter (ABCB4). The PC is solubilised from the outer 
leaflet to form a mixed micelle that reduces the detergent 
activity (and, therefore, the cytotoxicity) of the bile acids in 
the canalicular space of the biliary tree. Cells that line the 
biliary tree also express the P-type ATPase ATP8B1 that 
functions in complex with CDC50. ATP8B1/CDC50 flips a 
different phospholipid (phosphatidylserine) in the opposite 
direction to the PC flopped by ABCB4. This is thought to 
preserve the lipid asymmetry of the hepatocyte and chol-
angiocyte membranes that line the biliary tree to resist the 
detergent activity of the bile acids. These protective mech-
anisms are known to be critical for the health of the bil-
iary tree, because pedigree analysis shows definitively that 
mutations in ATP8B1 and ABCB4 cause two forms of fatal 
liver disease: Progressive Familial Intrahepatic Cholestasis 
(PFIC) types 1 and 3, respectively [2, 3]. These, and PFIC 
type 2 which is caused by ABCB11-deficiency [4], all result 
in end-stage liver disease in childhood, but the underly-
ing mechanisms are different: in type 1, the membranes of 
the biliary tree are more susceptible to detergent damage; 
in type 2, damaging levels of bile acids accumulate in the 
hepatocyte; and in type 3, unquenched bile acids accumu-
late in the canalicular space.
Heterozygous and non-synonymous variants in these 
genes have been associated with a spectrum of cholestatic 
conditions, including intrahepatic cholestasis of pregnancy 
(ICP), benign recurrent intrahepatic cholestasis, suscepti-
bility to drug-induced liver injury, and cholelithiasis (cho-
lesterol gallstones (CG) which, specifically for ABCB4 
SNPs, can develop into a syndromic condition termed low-
phospholipid associated cholelithiasis (LPAC) in Europe 
[5] and Oriental Cholangiohepatitis in Japan [6]). Recently, 
ABCB11 deficiency was also shown to be a driver of hepa-
tocellular cancer in children and mice via a mechanism 
that lacks a mutational signature of typical cancer genes, 
but which has an inflammatory basis leading to genome 
instability and amplification of the MAPK signalling path-
way [7]. Mice deficient in the PC-floppase ABCB4 (mdr2 
knock-out mice) do not fully develop PFIC type 3 because 
of the reduced toxicity of the rodent bile acid pool, but they 
do develop cholelithiasis [8] and inflammatory liver dis-
ease most similar to Sclerosing Cholangitis (SC) [9]. They 
also develop liver cancer [10, 11] via the same pathway 
of chronic inflammation that leads to genome instability 
and copy number gains in the MAPK signalling pathway 
[7]. ABCB4 non-synonymous SNPs have been reported 
in human patients with liver cancer (encoding variants 
I490T [12] and S978P [12]) and also in patients diagnosed 
with inflammatory liver diseases, such as SC (and LPAC; 
R545C [13, 14]) and Biliary Cirrhosis (BC; D243A [14], 
K435T [14] and G535D [15]), both of which are consid-
ered to predispose to the development of liver cancer 
[16–22]. The animal studies and these case reports suggest 
that ABCB4 deficiency can predispose to (at least a subset 
of) severe inflammatory liver diseases, but direct evidence 
of a deleterious effect of the non-synonymous changes at 
the protein level is lacking. Here, we address for the first 
time whether any of these six variants affect the stability, 
sub-cellular localisation or function of ABCB4, and thus 
are likely to cause cholestasis that predisposes to second-
ary chronic inflammation that would be required to drive 
the development of SC, BC, and liver cancer. Characterisa-
tion of these clinically relevant variants also provides novel 
insights into the molecular mechanism of action of ABC 
transporters. These are discussed in relation to the avail-
able molecular models and current theories of the transport 
cycle.
Materials and methods
Plasmids
Vector: pcDNA3-ABCB4, pcDNA3-ABCB4E558Q, pCINeo-
ATP8B1, and pCINeo-CDC50A were described previ-
ously [23]. pcDNA3-ABCB4D243A, pcDNA3-ABCB4K435T, 
pcDNA3-ABCB4I490T, pcDNA3-ABCB4G535D, pcDNA3-
ABCB4R545C, and pcDNA3-ABCB4S978P were generated by 
site-directed mutagenesis from pcDNA3-ABCB4.
Mutagenesis
Mutagenesis was performed using QuickChange-II XL 
Site-Directed Mutagenesis (Stratagene, San Diego, CA, 
USA). In each case, introduction of the clinically relevant 
SNP and the absence of additional mutations were verified 
by sequencing of the entire cDNA and promoter.
Mutagenic oligonucleotides
D243A, 5′-CTC TCG GCA TTT AGT GCC AAA GAA CTA 
GCT GCT TAT GC-3′.
K435T, 5′-GGA AGT AGT GGC TGT GGG ACG AGC 
ACA ACG GTC CAG CTG-3′.
I490T, 5′-GTT TTC CAC CAC AAT TGC TGA AAA TAC 
TTG TTA TGG CCGTG-3′.
G535D, 5′- GCC CAG CTG AGT GAT GGG CAG AAG 
CAG-3′.
R545C, 5′-GGA TCG CCA TTG CAT GTG CCC TGG 
TTCGC-3′.
S978P, 5′-CAG AGA TGT TAT TCT GGT GTT TCC TGC 
AAT TGT ATT TGG TGC A-3′.
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Culture conditions
HEK293T cells were grown as monolayers in Dulbecco’s 
modified eagle medium (DMEM) without phenol red but 
supplemented with 10% (v/v) heat-inactivated foetal calf 
serum, 100 U  ml−1 penicillin, 0.1  mg  ml−1 streptomycin, 
0.584 g/L L-glutamine, and 1 mM sodium pyruvate, under 
5%  CO2 at 37 °C with a water vapour saturated atmosphere 
(Galaxy 170  S; New Brunswick Scientific, Edison, NJ, 
USA).
Preparation of crude cell lysates and Western analysis
HEK293T cells (4.5 × 105) were seeded as a monolayer 
on 6-well plates (ThermoFisher Scientific, Waltham, MA, 
USA) in 2 ml medium 24 h prior to transfection. The trans-
fection mixture (7.5 μg total plasmid DNA in 0.5% (w/v) 
glucose mixed with 1.5  μl polyethyleneimine (PEI) and 
adjusted to a final volume of 10 μl with sterile water) was 
prepared in individual 1.5 ml eppendorf test tubes (Eppen-
dorf, Hamburg, Germany) and incubated for 10  min at 
room temperature (RT). PEI was prepared by dissolving 
45 mg PEI in 8 ml sterile water, corrected to pH 7.2 with 
dilute HCl, passed through a sterile filter (0.2 μm) and kept 
at RT. For transfections with plasmid DNA encoding only 
wild-type (WT) or variant ABCB4, the transfection mixture 
contained 2.5 μg of ABCB4-encoding plasmid and 5 μg of 
empty pCINeo vector. For transfections with three differ-
ent plasmids encoding ATP8B1 and CDC50A plus either 
WT or variant ABCB4, the transfection mixture contained 
2.5 μg of each plasmid. After 10 min incubation, 2 ml fresh 
medium, pre-warmed to 37 °C, was added to each tube and 
the mixture applied directly to the cells. Under these condi-
tions, we have shown previously that 60% of the cells in 
the population are transfected and that 96% of these cells 
that take up one plasmid, take up all three [24]. Transfected 
cells were grown for 48 h before monolayers were washed 
twice with phosphate buffered saline (PBS) and harvested 
in lysis buffer (150 mM NaCl, 20 mM HEPES pH 7.4, 1% 
SDS), 1 × EDTA-free complete protease inhibitor cocktail 
(Roche, Basel, Switzerland), 1 mM PMSF (Sigma, St Luis, 
MO, USA). Following denaturation in Laemmli sample 
buffer (5 min, 70 °C), 2 μg of each crude lysate was sepa-
rated by SDS–PAGE and transferred to polyvinylidene dif-
luoride membrane (PVDF, Millipore, Billerica, MA, USA) 
overnight at a constant voltage (20 V). Blots were probed 
with either mouse anti-ABCB4 diluted 1 in 5,000 (mono-
clonal  P3II-26, Sigma, St Louis, MO, USA) or mouse 
anti-β-tubulin diluted 1 in 6,000 (SourceBioscience, Not-
tingham, UK). Binding of  P3II-26 and anti-β-tubulin was 
then detected using goat anti-mouse secondary, conjugated 
to horseradish peroxidase diluted 1 in 2,000 (Santa Cruz, 
Dallas, TX, USA), for visualisation by chemiluminescence 
(ECL; GE Healthcare, Little Chalfont, UK). Exposed 
X-ray film (GE Healthcare, Little Chalfont, UK) was then 
scanned to allow quantitative analysis of protein abundance 
by densitometry using the Fiji software suite [25].
Protein deglycosylation
For removal of N-linked glycans, crude lysate from triple-
transfected cells (5  μg total protein for WT samples and 
20 μg for  ABCB4R545C samples) was incubated for 10 min 
at 100 °C in the presence of denaturant (0.5% SDS, 40 mM 
DTT) before buffering with  NaH2PO4 [to a final concentra-
tion of 50 mM, pH 7.5 (at 25 °C)], and addition of NP-40 
(to 1% final concentration). Deglycosylation was carried 
out with 500U of PNGase F (New England Biolabs) for 2 h 
at 37 °C, before separation of protein by SDS–PAGE and 
Western analysis, probed with the C219 antibody (Dako 
Ltd UK).
PC‑efflux assay
Six-well plates were treated with 1  ml Poly-L-lysine for 
1 h at RT and washed three times in 1 ml Dulbecco’s phos-
phate buffered saline (DPBS). HEK293T cells (4.5 × 105) 
were seeded on the pre-treated plates 24 h prior to transfec-
tion. The cells were always triple transfected to co-express 
ATP8B1, CDC50, and ABCB4 wild-type or variant (as 
described above). Twenty-four hours post-transfection, 
the cells were fed 2 μCi [methyl-3H]choline (PerkinElmer, 
Waltham, MA, USA) and cultured for 24 h. The medium 
was removed and cells were washed three times in 1  ml 
fresh medium pre-warmed to 37 °C, and then incubated in 
2 ml medium supplemented with 2 mM sodium taurocho-
late hydrate (TC) (Sigma, St Luis, MO, USA). After 24 h 
incubation, 50 μl of culture media from each well were ana-
lysed for radioactivity content in a Beckman LS 6000SC 
scintillation counter (Beckman Coulter, Fullerton, CA, 
USA). The cells attached to the dish were washed three 
times in 1 ml DPBS and lysed in 2 ml 0.5% (v/v) Triton-X 
100. An aliquot (50 μl) from each lysate was analysed for 
radioactivity to determine the cellular radioactive content. 
PC efflux was calculated as PC detected in the media as a 
percentage of the total (media plus lysate), then normalised 
against an internal non-functional control; the Walker B 
mutant,  ABCB4E558Q.
Sub‑cellular localisation of ABCB4
Sterile coverslips were placed into each well of a 12-well 
plate (ThermoFisher Scientific, Waltham, MA) and treated 
with 100 μl Poly-L-Lysine for 1 h at RT followed by three 
washes in 1  ml DPBS. The wells were then seeded with 
HEK293T cells (1.5 × 105) in 1  ml medium 24  h prior to 
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transfection. On the day of transfection, the cells were 
triple-transfected as described above but scaled down to 
the 12-well format. Forty-eight hour post-transfection, 
the medium was aspirated from the wells, the cells were 
washed three times in 1 ml PBS and then fixed with ice-
cold 10% (v/v) acetone in ethanol, for 20 min at RT. Fol-
lowing three washes in PBS, the cells were blocked for 1 h 
at RT in 1  ml of 5% (w/v) BSA (bovine serum albumin; 
Sigma, St Louis, MO, USA) in PBS. The cells were washed 
three times in 1  ml PBS before incubating the coverslips 
with 50  μl of the anti-ABCB4 antibody,  P3II-26 [50  μg 
 ml−1 in 1% (w/v) BSA in PBS (Sigma, St Louis, MO, 
USA)] and/or anti-Na+/K+-ATPase antibody H-300 [50 μg 
 ml−1 in 1% (w/v) BSA in PBS (Santa Cruz, Dallas, TX, 
USA)] for 1 h at RT. Following three washes in 1 ml PBS, 
the coverslips were incubated with 50 μl of Alexa Fluor® 
568 Dye-conjugated goat anti-mouse IgG and/or Alexa 
Fluor® 488 donkey anti-rabbit IgG [2  μg  ml−1 (Invitro-
gen, Carlsbad, CA, USA) in 1% (w/v) BSA in PBS] for 1 h 
at RT. Nuclei were stained in the same incubation period 
with 1.5  ng μl−1 DAPI (4′,6-diamidino-2-phenylindole; 
Invitrogen, Carlsbad, CA, USA). The coverslips were then 
washed three times in 1 ml PBS and mounted onto micro-
scope slides using  FluorSave™ Reagent (Millipore, Biller-
ica, MA, USA). Cells were viewed using a Zeiss LSM710 
confocal laser scanning microscope based on an Axiovert 
inverted microscope (Carl Zeiss, Oberkochen, Germany) 
with a 63 × oil immersion objective and a numerical aper-
ture of 1.4. Laser lines 488, 568, and 405 nm were used to 
excite Alexa Fluor® 488/568 and DAPI, respectively. The 
pinhole was set to 1 Airy unit at 2.0% laser power for all 
experiments. Images were acquired with sequential scan-
ning to allow cross-talk free Alexa Fluor® 488/568 and 
DAPI images to be collected. Images were depixelated and 
background was subtracted before co-localisation analyses 
(coloc 2) in the Fiji software suite.
Results
Expression levels of the ABCB4 variants in HEK293T 
cells and a first indication of functionality
Wild-type ABCB4 is cytotoxic to HEK293T cells and 
expresses very poorly by itself. Expression can be rescued 
and the cytotoxicity reduced to background levels by co-
expression of the phosphatidylserine flippase ATP8B1/
CDC50 [23]. We have shown previously that the del-
eterious effect on the host cell is a direct consequence of 
ABCB4 PC-floppase activity [23, 24], which is why the 
inactive Walker B mutant  ABCB4E558Q that lacks the cata-
lytic base required for ATP hydrolysis, expresses to a high-
level irrespective of the ATP8B1/CDC50 status (Fig.  1a, 
b). Western analysis can, therefore, be a useful first indi-
cation of the effect of non-synonymous mutations, provid-
ing information on protein abundance (a combination of 
translation, and protein folding and stability) and of func-
tion (because high-level expression of ABCB4 variants in 
the absence of ATP8B1/CDC50 suggests low PC-efflux 
activity). The D243A, K435T, G535D, R545C, I490T, and 
S978P variants were engineered into pcDNA3-ABCB4 to 
mimic the SNPs reported in patients. HEK293T cells were 
transfected transiently, with either three plasmids encoding 
ABCB4 (the wild-type (WT) transporter or a variant or the 
catalytically inactive  ABCB4E558Q mutant) plus ATP8B1 
and CDC50, or encoding an ABCB4 plus two aliquots of 
empty vector.
The expression levels of the variants were assessed by 
Western analysis in the presence and absence of ATP8B1/
CDC50 and the abundance of each was quantified and 
compared to that of the wild-type and  ABCB4E558Q pro-
teins (representative blots are shown in Fig.  1a and repli-
cate data sets are quantified in Fig. 1b). The novel variants 
linked to inflammatory liver diseases displayed a range of 
phenotypes. The two variants directly linked to liver can-
cer,  ABCB4I490T and  ABCB4S978P, expressed at reduced 
levels, 6 and 22%, respectively, relative to the expression 
of the WT transporter in the presence of ATP8B1/CDC50. 
The  ABCB4I490T signal needed longer exposure time to 
visualise and a more complex pattern was evident with two 
prominent small molecular weight species in addition to 
the full-length 160 kDa species (for the purpose of quanti-
fication, only the level of the mature 160 kDa species was 
measured, see below for explanation). Co-expression of 
ATP8B1/CDC50 had no statistically significant effect on 
the expression level of these variants. Of the variants linked 
to the development of biliary cirrhosis,  ABCB4D243A has 
an expression profile that is indistinguishable statistically 
from that of the wild-type transporter, while  ABCB4K435T 
and  ABCB4G535D expressed to equally high levels in the 
presence and absence of ATP8B1/CDC50 and could not 
be distinguished statistically from the catalytically inactive 
 ABCB4E558Q mutant. The variant linked to the develop-
ment of sclerosing cholangitis,  ABCB4R545C, expressed at 
a lower level and migrated primarily as two protein species 
on the gel (the abundance of the larger, 160 kDa, species 
measured 17% of the wild-type transporter). Enzymatic 
deglycosylation of the sample resolves the two species 
into a single species that migrates with the same mobility 
as the deglycosylated wild-type transporter (Fig.  1c). The 
two species of  ABCB4R545C therefore differ in glycosyla-
tion status suggesting that the faster migrating species is 
immature protein (probably in the endoplasmic reticulum) 
and the slower migrating 160 kDa species is the fully gly-
cosylated mature protein that could be present anywhere 
from the terminal cisternae of the Golgi apparatus where 
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the glycans are matured, to the plasma membrane or recy-
cling vesicles.
ABCB4D243A,  ABCB4G535D,  ABCB4K435T, 
and  ABCB4S978P localise primarily to the plasma 
membrane, but significant fractions of  ABCB4I490T 
and  ABCB4R545C are retained intracellularly
Cells were transiently transfected to express ABCB4 and 
ATP8B1/CDC50 then fixed, permeabilised and stained for 
ABCB4, and also the  Na+/K+ ATPase as a plasma mem-
brane marker. Confocal microscopy showed that the WT 
protein traffics efficiently to the plasma membrane where it 
co-localises with  Na+/K+ ATPase giving a high Mander’s 
coefficient (0.687), with little signal detected intracellularly 
(Fig. 2).  ABCB4D243A and  ABCB4K435T also show evidence 
of co-localisation with  Na+/K+ ATPase with similar Man-
der’s coefficients to the wild-type transporter. Together 
with the Western blot data which show similar expression 
levels for the 160  kDa mature species of the wild-type 
and these variants, it seems reasonable to conclude that 
 ABCB4D243A and  ABCB4K435T are present in the plasma 
membrane at similar levels to the wild-type transporter. 
 ABCB4G535D and  ABCB4S978P also have high Mander’s 
coefficients of 0.439 and 0.453, respectively for overlap 
with the  Na+/K+ ATPase, suggesting that almost half of the 
mature protein observed on their respective Western blots is 
localised to the plasma membrane. In contrast,  ABCB4I490T 
and  ABCB4R545C were observed largely in an intracellular 
compartment, with a little overlap with the plasma mem-
brane marker (Mander’s coefficients of 0.067 and 0.068, 
respectively). This is consistent with the presence of lower 
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Fig. 1  Expression of ABCB4 variants in the presence and absence 
of ATP8B1/CDC50 and glycosylation status of the R545C variant. 
Abundance of ABCB4 variants D243A, K435T, G535D, R545C, 
I490T, and S978P was examined by Western analysis of whole-cell 
lysates from transiently transfected HEK293T cells, in the presence 
and absence of ATP8B1/CDC50. a Representative Western blots 
showing the expression levels of the variants with respect to the 
wild-type (WT) transporter and the catalytically inactive Walker B 
mutant (WB). ABCB4 was detected by monoclonal antibody  P3II-26. 
Tubulin was used as a loading control. b Biological replicates (n ≥ 3) 
were digitised and quantified by densitometry. The plot shows mean 
arbitrary units of expression level + s.e.m. normalised to the internal 
wild-type control (WT in the presence of ATP8B1/CDC50). Statis-
tical analysis was by unpaired Student’s t test and compares expres-
sion level in the presence and absence of ATP8B1/CDC50, showing 
significant difference for WT and D243A samples. The expression 
levels of I490T, R545C, and S978P are also statistically lower than 
the level of wild-type ABCB4 in cells expressing ATP8B1/CDC50 
(n ≥ 3; ***p < 0.001, **p < 0.01, *p < 0.05). c Aliquots (5 and 20 μg 
total protein for the WT and R545C samples, respectively) were sub-
jected to PNGase F digestion or left untreated, as indicated. Western 
was probed with monoclonal anti-ABCB4 antibody C219
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molecular weight species of both variants in Western blot. 
The lack of mature glycans on the lower molecular weight 
species of  ABCB4R545C (Fig. 1c) is consistent with a stain-
ing pattern localised primarily to the nuclear periphery 
suggesting that this variant folds inefficiently and is largely 
retained within the ER. Although we have not shown that 
 ABCB4I409T is differentially glycosylated, we tentatively 
suggest from the staining pattern that this variant is also 
likely to fold inefficiently and may be targeted for degrada-
tion via the ER-associated degradation pathway resulting in 
the low levels detected on Western blot (Fig. 1a).
ABCB4D243A is partially active,  ABCB4K435T 
and  ABCB4G535D are inactive, and efflux of PC 
from cells expressing  ABCB4I490T,  ABCB4R545C 
and  ABCB4S978P was not detected
HEK293T cells were transfected to express ATP8B1/
CDC50 plus wild-type or variant ABCB4. Twenty-four 
hour post-transfection, the cells were fed 3H-choline to 
convert into 3H-PC. Previously, we have shown that cel-
lular efflux of PC is dependent on bile salts, taurocholate 
was therefore added 48 h post-transfection to extract the 
flopped radiolabelled PC from the outer leaflet of the 
plasma membrane. PC is a normal component of plasma 
membranes and is enriched in the outer leaflet. 3H-PC 
can therefore be extracted from naïve cells which do 
not express ABCB4, or from cells expressing the cata-
lytically inactive Walker B mutant  ABCB4E558Q. How-
ever, significantly more 3H-PC is extracted from cells 
expressing wild-type ABCB4 due to the activity of the 
transporter (Fig. 3a). 3H-PC efflux via  ABCB4D243A was 
also significantly above background but consistently less 
than from the wild-type transporter. In paired experi-
ments, 3H-PC efflux from cells expressing  ABCB4D243A 
was on average 56%+/−0.16% of the wild-type level. For 
 ABCB4K435T and  ABCB4G535D, there was no evidence 
of any 3H-PC efflux, as expected from the Western data, 
because the high expression levels of these variants in the 
absence of ATP8B1 and CDC50 implied a lack of cyto-
toxicity and, therefore, a lack of transport activity. With 
 ABCB4K435T and  ABCB4G535D trafficking to the plasma 
membrane relatively efficiently, it is evident that these 
variants are mechanistically impaired. No 3H-PC-efflux 
activity was observed for  ABCB4I490T,  ABCB4R545C, and 
 ABCB4S978P. The levels of 3H-PC extracted by the added 
Fig. 2  Confocal analysis of ABCB4 variant sub-cellular localisa-
tion. Trafficking of ABCB4 mutants D243A, K435T, G535D, R545C, 
I490T, and S978P was examined by confocal microscopy (shown 
in magenta in the merged images) in cells co-expressing ATP8B1/
CDC50. The  Na+/K+ ATPase, shown in green in the merged images, 
marks the plasma membrane. Co-localisation in the merged image is 
white when the pixels for the  Na+/K+ ATPase and ABCB4 overlap 
and have the same intensity. The Mander’s coefficient for the given 
field of view provides a measure of this co-localisation above a calcu-
lated threshold, irrespective of pixel intensity
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taurocholate were significantly reduced compared to that 
extracted from cells expressing the WT protein (Fig. 3a), 
but not significantly different from the background level 
from the E558Q Walker B mutant cells. It is possible that 
the low levels of expression of these variants, in particu-
lar for  ABCB4I490T and  ABCB4R545C for which signifi-
cant fractions appear immature and/or retained intracel-
lularly, fall outside the sensitivity of the functional assay 
and that function could be rescued by improving their 
proteostasis properties.
The molecular chaperone cyclosporin A increases 
the stability of  ABCB4S978P and wild‑type ABCB4, 
but has no effect on the abundance of  ABCB4I490T 
or  ABCB4R545C
Previously, cyclosporin A (CsA) has been shown to 
improve the folding kinetics of mutants of the multid-
rug efflux pump ABCB1, leading to improved stabil-
ity, increased trafficking to the plasma membrane, and 
increased function [26]. We have shown that CsA can 
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Fig. 3  PC-efflux activity of ABCB4 variants and response of vari-
ants with poor proteostasis characteristics to a molecular chaper-
one. a Cells expressing ATP8B1/CDC50 and ABCB4 (wild-type or 
variant) were fed tritiated choline to measure PC efflux. Background 
PC flux has been accounted for by subtraction of the level extracted 
from cells expressing the catalytically inactive Walker B mutant 
E558Q. Mean efflux activity + s.e.m. are plotted. Statistical analysis 
was by the one-way analysis of variance with Tukey’s multiple com-
parison test to compare the efflux activity to the wild-type ABCB4 
(n ≥ 4; ***p < 0.001, **p < 0.01, *p < 0.05). b Cells expressing 
ATP8B1/CDC50 and ABCB4 (wild-type or variants  ABCB4I490T, 
 ABCB4R545C and  ABCB4S978P) were treated with CsA, as indicated. 
Western analysis was used to assess the ability of CsA to rescue the 
variant phenotypes. Mean expression level + s.e.m. are plotted. Sta-
tistical analysis was by unpaired Student’s t test and compares the 
expression level to the equivalent ABCB4 in the presence of vehicle 
(DMSO) but absence of CsA (n = 4; *p < 0.05, **p < 0.01). c Sub-
cellular localisation of I490T, R545C, and S978P in cells treated with 
10  μM CsA from 24  h post-transfection was analysed by confocal 
microscopy. ABCB4 is shown in magenta and the  Na+/K+ ATPase is 
shown in green as a marker of the plasma membrane. Faint staining 
of  ABCB4I490T at the periphery of cells (not seen in the absence of 
CsA) is indicated by the magenta arrows. d Mander’s coefficients for 
overlap of ABCB4 (magenta pixels) with the  Na+/K+ ATPase (green 
pixels) independent of pixel intensity were calculated for three fields-
of-view
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also stabilise the expression of specific ABCB4 mutants, 
albeit at the cost of irreversible PC-efflux inhibition [24]. 
The primary phenotype of  ABCB4I490T,  ABCB4R545C, and 
 ABCB4S978P is low abundance. To test if their expression 
levels could also be rescued by CsA, ATP8B1, CDC50, 
and ABCB4 encoding the variant or wild-type transport-
ers were transiently expressed in HEK293T cells. Twenty-
four hours post-transfection, the cells were incubated with 
increasing concentrations of CsA. After a further 24  h, 
the cells were harvested for Western analysis. None of the 
ABCB4 mutants were fully rescued to the wild-type level 
of expression, but  ABCB4S978P expression was improved, 
trending upward in a dose-dependent manner to achieve a 
statistically significant three-fold increase with 10 μM CsA 
(Fig. 3b). This provides proof of principle that intervention 
to improve the abundance of  ABCB4S978P in patient liv-
ers might alleviate cholestatic symptoms. The abundance 
of  ABCB4I490T and  ABCB4R545C was insensitive to CsA. 
However, the increase in stability of the wild-type protein 
in response to the drug shows that molecular chaperones 
could also be efficacious in patients heterozygous at the 
ABCB4 locus with the wild-type allele.
Cyclosporin A has a subtle effect on the localisation 
of  ABCB4I490T at the plasma membrane
CsA has previously been shown to increase the localisa-
tion of the  ABCB4A935D mutant (a cause of PFIC3) to the 
plasma membrane without increasing its abundance in the 
cell [24]. We therefore tested whether CsA would affect 
the sub-cellular localisation of  ABCB4I490T,  ABCB4R545C 
or  ABCB4S978P. A subtle increase in the Mander’s coeffi-
cient for overlap with the  Na+K+ATPase was observed, in 
particular, for  ABCB4I490T in the presence of 10 μM CsA 
(Fig. 3c); however, this did not reach statistical significance 
when multiple fields were analysed (Fig.  3d). Wild-type 
ABCB4 in the presence and absence of CsA is shown for 
comparison. Importantly, the >twofold increase in expres-
sion of  ABCB4WT following treatment with CsA (Fig. 3b) 
has not negatively affected the Mander’s coefficient 
(Fig. 3d), indicating that the additional protein is located at 
the plasma membrane.
Discussion
Mice deficient in Abcb4 develop liver cancer as a result of 
chronic inflammation. In humans, non-synonymous SNPs 
in ABCB4 have been identified in patients with liver can-
cer (cholangiocarcinoma; Table  1) [12]. In both of the 
patient case studies, relatives heterozygous for the same 
I490T and S978P variants presented with cholestatic dis-
eases that are more commonly associated with ABCB4 
dysfunction, suggesting that pre-existing cholestasis may 
also predispose to cancerogenesis in humans. Population 
genetic studies have also linked ABCB4 variants to the 
Table 1  Patient histories and protein phenotypes of the ABCB4 SNPs linked to inflammatory liver disease
The population genetic study of Pauli-Magnus et al. [14] describes the diagnoses as Primary Sclerosing Cholangitis and Primary Biliary Cirrho-
sis, although we would argue that the conditions are likely secondary to underlying inflammatory cholestasis in these patients
CG cholesterol gallstones (cholelithiasis), BC biliary cirrhosis, SC sclerosing cholangitis, ICP intrahepatic cholestasis of pregnancy, LPAC 
low phospholipid-associated cholelithiasis
a Daughter of the patient above
b Sister of patient above
c Cells expressing these mutants do not efflux significant levels of PC, but this could due to a lack of the transporter at the plasma membrane 
(pm), rather than the inactivity of the protein
SNP Protein References Sex Zygosity History Amino-acid posi-
tion
Abundance Localisation PC-efflux activity
A728C D243A [14] Unknown Unknown BC TMD1 TMH4 Normal pm Half
A1304C K435T [14] Unknown Unknown BC NBD1 Walker A 
motif
Normal pm Inactive
T1469C I490T [12] Male Heterozygous Carcinoma NBD1 α-helical 
subdomain
Low (6%) Intracellular Unknownc
T1469C I490T [12] Femalea Heterozygous CG, Jaundice, 
Pruritis
G1606A G535D [15] Female Heterozygous CG, ICP, BC NBD1 ABC sig-
nature motif
Normal pm Inactive
G1606A G535D [15] Femalea Heterozygous ICP
C1633T R545C [14] Unknown Unknown SC NBD1 α-helical 
subdomain
Low (17%) Intracellular Unknownc
T2932C S978P [12] Female Heterozygous Carcinoma TMD2 TMH12 Low (22%) pm Unknownc
T2932C S978P [12] Femaleb Heterozygous LPAC, ICP
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development of inflammatory cholangiopathies, sclerosing 
cholangitis, and cirrhosis [14] that are already considered 
to predispose to cholangiocarcinoma [16–18, 21, 22]. (It is 
important to stress here that the population genetics have 
shown that variation at the ABCB4 locus is not a strong 
determinant of primary sclerosis cholangitis or primary 
biliary cirrhosis, but the SNPs encoding D243A, K435T, 
and R545C were observed only in the patient cohort and 
not in the healthy controls. Others have already speculated 
that this may reflect a heterogeneous etiology of these con-
ditions in which a subset is linked to ABCB4 deficiency 
[27]). A further case study also linked the G535D variant 
to development of cirrhosis in a patient who also has a fam-
ily history of cholestatic disease (Table  1) [15]. Combin-
ing what is already known about the role of ABCB4 in 
bile formation and flow, with the animal data and human 
genetic data, it seems plausible that ABCB4 SNPs under-
lie the inflammatory liver disease in these patients. What 
is missing is evidence of cause and effect at the level of the 
transporter. We, therefore, engineered the SNPs into the 
ABCB4 cDNA to test whether the non-synonymous amino-
acid changes negatively affect transporter expression and/
or function and expressed these transiently in a human cell 
line. A hepatocyte cell line would not have been appropri-
ate for this purpose because of the co-ordinate regulation 
of the bile flow transporters and their potential induction 
by the need to add bile salts to solubilise the flopped PC. 
HEK293T cells were selected as the host cell because they 
lack endogenous ABCB4 expression and are readily trans-
fected (very high levels of co-transfection were necessary 
to express ATP8B1 and CDC50 with ABCB4 in the same 
cells). While the HEK293T cells express wild-type ABCB4 
efficiently at the plasma membrane, they have limitations as 
a host cell, because they not polarised and may lack hepat-
ocyte-specific factors that could affect the protein folding 
and trafficking landscape.
All of the variants significantly impaired the ability of 
ABCB4 to secrete PC from cells but their phenotypes at the 
protein level were distinct (Table 1). Prior work on different 
SNPs indicated that ABCB4-haploinsufficiency can result 
in clinical symptoms, and the in vitro activity of the mutant 
floppases correlated well with disease severity after allelic 
heterogeneity was accounted for [24]. Using these data as 
a prognostic barometer, individuals with half the PC-flop-
pase activity (the expected level of activity in patients with 
 ABCB4K435T,  ABCB4I490T,  ABCB4G353D,  ABCB4R545C, 
or  ABCB4S978P in heterozygosity with the wild-type 
allele) would be expected to present with clinical choles-
tasis. Clinical symptoms are also evident in patients with 
a genotype that equates to 75% of the normal PC-floppase 
activity  (ABCB4wild−type/ABCB4S320F). The previously 
characterised  ABCB4S320F was found to be fully active, 
but expression was reduced by half, compared to the WT. 
 ABCB4D243A is similar, because, although its abundance 
is normal, it only flops half the PC of the WT transporter. 
It is reasonable to expect, therefore, that the ABCB4 geno-
type of the patients in the current study causes a chronic 
cholestatic phenotype due to canalicular bile salt micelles 
that are low in PC. The ensuing damage to the biliary tree 
would likely produce an inflammation response that drives 
secondary sclerosis or cirrhosis, and predisposes to liver 
cancer [28, 29], as observed in the animal models [30–32].
Mechanistic implications
Both  ABCB4K435T and  ABCB4G535D express well irrespec-
tive of ATP8B1/CDC50 status and localise to the plasma 
membrane but lack PC-floppase activity. Both of these 
residues are in highly conserved motifs within the first 
nucleotide-binding domain (NBD1) of ABCB4 (Fig. 4a, b). 
K435 is part of the Walker A motif  (GxxGxGK435ST) and 
G535 is part of the ABC signature motif  (LSG535GQ) that 
are critical for the binding of ATP at the interface between 
the two NBDs. The two motifs affect different ATP-binding 
pockets (Fig.  4b), because two molecules of ATP are co-
ordinated at the interface between the Walker A motif of 
one NBD and the ABC signature of the other NBD. Current 
thinking on the transport cycle of an efflux ABC transporter 
is shown in Fig. 4a as the transition between three confor-
mational states (derived from the models of three different 
ABC transporters, each crystallised in a different confor-
mation). Interpreting these models with respect to ABCB4, 
the inward-open state depicted by model of Abcb1a on the 
left should bind PC from the inner leaflet of the membrane 
(the so-called elbow helix is considered to be cytosolic but 
juxtaposed to the head groups of the membrane lipids of 
the inner leaflet). The binding of PC would be hypothesised 
to induce the conformational change to the closed state (the 
model of McjD) which requires two ATPs to be bound at 
the interface between the NBDs. This fully closed state is 
likely to be transient, progressing to the outward-open con-
formation (Sav1866 model; although crystallised with two 
ADPs at the NBD:NBD interface, it is generally considered 
to reflect the ATP-bound conformation). With respect to 
ABCB4, we speculate that the outward-open conformation 
releases PC (into the outer leaflet, or directly into a bile salt 
micelle) and ATP hydrolysis would drive the transporter 
back into the inward-open conformation. Phenotypically, 
the K435T and G535D variants appear similar to the cata-
lytically inactive Walker B mutant E558Q, but, mechanisti-
cally, they are likely to interrupt the transport cycle at an 
earlier step, because they would be expected block ATP 
binding to one or the other binding pocket and so prevent 
the transition between the inward-open and inward-closed 
states, whereas the Walker B mutant would block the return 
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of the outward-open state to the inward-open state by pre-
venting ATP hydrolysis.
The I490T and R545C variants of ABCB4 express only 
to low levels compared to the wild-type transporter and 
are largely retained intracellularly. Extrapolating from the 
available structural data, I490 and R545 are located within 
5 Å of each other in the tightly folded alpha-helical subdo-
main that forms the ABC signature motif (Fig.  4b). Both 
variants change the size and polar nature of the side chain 
and are therefore likely to influence the folding kinetics of 
the subdomain. In particular, the side chain of R545, which 
is in the same helix as the ABC signature motif, appears to 
form several hydrogen bonds that are likely important for 
the integrity of the motif’s structure; these would be lost in 
the R545C variant. Poor folding kinetics in this subdomain 
most likely results in the nascent protein being held in the 
endoplasmic reticulum before degradation by the quality 
control process, which would fit with the observed glyco-
sylation differences and the low abundance of these vari-
ants at the plasma membrane.
ABCB4D243A is the least debilitated of the variants. It 
expresses to the level of the wild-type protein, and localises 
to the plasma membrane. It also remains cytotoxic to the 
HEK293T cells in the absence of ATP8B1/CDC50, but it is 
not fully functional and only secretes 56% of the PC com-
pared to the wild-type transporter. D243 is located towards 
the intracellular end of transmembrane helix (TMH) 4 of 
the first TMD. In Fig. 4c, a 30 Å slab showing the trans-
membrane helices at the intracellular face of the inward-
open and inward-closed models is shown (the elbow heli-
ces which are cytosolic are also visible within the slab, 
and allow ease of reference to the models in Fig.  4a). In 
Fig. 4  Molecular modelling of the impact of the non-synonymous 
amino-acid changes on ABC transporter fold and function. Cartoon 
representation of three conformations of ABC exporters observed in 
X-ray crystallographic studies. The inward-open state of Abcb1a (pdb 
3G5U [33]) is nucleotide-free and considered to be the high affinity 
state for binding transport substrate. The occluded, closed state of 
McjD (pdb 4p10 [34]), crystallised with two molecules of non-hydro-
lysable ATP analogue shown in ball and stick form, is considered to 
represent an intermediate state of the transport cycle with transport 
substrate and ATP bound. The outward-open state of Sav1866 (pdb 
2HYD [35]), crystallised with two molecules of ADP shown in ball 
and stick format (although the NBD:NBD interface is considered to 
represent the ATP-bound state), is thought to depict the conformation 
after release of the transport substrate but prior to ATP hydrolysis. 
ATP hydrolysis and ADP and phosphate release should restore the 
transporter to the Abcb1a conformation. In all models, the equivalent 
residues (identified by alignment of the primary sequences by Clustal 
W) to ABCB4 D243, K435, G535, I490, R545, and S978 are shown 
as spheres and coloured elementally. The likely position of the mem-
brane is indicated, with the head groups of the inner leaflet mem-
brane lipids just above the elbow helices. b Close-up view of NBD1 
(based on McjD) from the perspective of NBD2 showing the position 
of K435 in the Walker A motif, I490 and R545 in the α-helical sub-
domain and G535 in the ABC signature motif of the α-helical sub-
domain. The ATPs are shown in transparent ball and stick format. 
NBD2 and TMD2 are hidden for clarity. c A 30 Å slab viewed from 
above the plane of the membrane, showing the TM helices at the 
intracellular face of the membrane and the changing position of D243 
and K244 as the transporter moves from the inward-open (Abcb1a) to 
the outward-open (Sav1866) conformation
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the inward-open model (Abcb1a), the side chain of D243 
is orientated towards the central cavity formed by the 
transporter, but in the inward-closed model (Sav1866), 
the equivalent side chain (a glutamate) is orientated to the 
periphery of the protein. In ABCB4, the adjacent residue 
is a lysine (K244), and in the drug efflux pumps, Abcb1a 
and Sav1866, the adjacent residues are lysine and argi-
nine, respectively. We speculate that as the inward-open, 
central cavity is closed TMH4 rotates to move the nega-
tively charged D243 residue out of the cavity to be replaced 
with a positively charged K244 residue. The choline head 
group of PC carries a positive charge, and the drugs trans-
ported by Abcb1a and Sav1866 often contain a single cati-
onic group, suggesting that electrostatic attraction may be 
important for substrate binding within the inward-open 
cavity (Abcb1a model) which converts to electrostatic 
repulsion to drive the substrate across the membrane as 
the transporter changes to the outward-open conformation 
(Sav1866 model). Replacing the negatively charged side 
chain of the aspartate with the smaller neutral side chain of 
alanine would reduce the electrostatic potential in the bind-
ing cavity of the transporter. Further investigation will be 
needed to confirm this hypothesis.
S978 is also located within a transmembrane domain, 
towards the extracellular end of TMH12.  ABCB4S978P 
expression is low, although it traffics to the plasma mem-
brane efficiently with very little observed intracellularly. 
PC flopping activity is not significantly different to the cat-
alytically inactive Walker B mutant. S978 is conserved in 
Abcb1a and in the inward-open configuration its side chain 
is orientated towards the apex of the central cavity, where 
it has been shown to interact with an inhibitor of the trans-
porter [36]. The relevance of this is unclear for PC flop-
ping by ABCB4, but the equivalent residues (tyrosines that 
preserve the hydroxyl moiety of the side chain) in McjD 
and Sav1866 (the closed and outward-open states, respec-
tively) are re-orientated away from the central cavity. Pro-
line residues cannot donate hydrogen bonds and are known 
to disrupt alpha-helices. They are rare in TMHs where they 
typically introduce a kink in the helix. As  ABCB4S978P 
can be observed in the plasma membrane (with little seen 
in the ER), it may be that this non-functional variant with 
a kinked TMH12 is turned over more rapidly which could 
contribute to the low abundance observed.
In summary, we have demonstrated that ABCB4 SNPs 
encoding D243A, K435T, G535D, I490T, R545C, and 
S978P significantly compromise the transporter. Compari-
son to a prognostic scale suggests that each would cause 
cholestasis even if the second allele is wild-type. Indeed, 
all of these variants would be expected to cause PFIC3 in 
the homozygous state (perhaps except  ABCB4D243A, which 
might, nevertheless, predispose to developing late onset 
PFIC3 similar to individuals homozygous for  ABCB4S320F 
[24]). Together with the genetic evidence, patient histories, 
and animal studies, these data at the protein level provide a 
compelling argument that the ABCB4 genotype can under-
lie development of inflammatory liver diseases that extends 
to cancer. Management and treatment options should there-
fore include addressing the underlying cholestasis, and may 
be helped by future development of drugs that improve the 
proteostasis of the wild-type allele but do not inhibit its 
transport activity.
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